Controlled delivery of Rivastigmine (cas 123441-03-2) using transdermal patch for effective management of alzheimer's disease

Add time:07/24/2019    Source:sciencedirect.com

Alzheimer's disease is a chronic neurodegenerative disease. Preparation of transdermal patches is a useful strategy for management of the disease. The transdermal patches bearing Rivastigmine (cas 123441-03-2) tartarate were prepared using solvent casting method to provide good drug content uniformity. Transdermal patches were characterized for various attributions viz. patch weight, patch thickness, folding endurance, surface morphology study, X-Ray diffraction study, Differential Scanning Calorimetry, tensile strength, surface pH, percent swelling, percent moisture sorption, drug content uniformity, In vitro release study, and ex-vivo study. Results of in vitro drug release studies clearly indicate that the drug release governed polymer interaction. No lag time was observed then reduction in drug release rate was observed. Extended drug release of 75.15 ± 1.43% within 24 h was observed with formulation. The results of the permeation study indicated that the rate of drug permeation was slow and it was found that 61 ± 1.43% of Rivastigmine tartrate could permeate through the skin membrane in 24 h. In the light of the above mentioned considerations, it is clear that the developed transdermal patch bearing Rivastigmine tartrate was retained in skin layer and delivers the therapeutic amount of drug in blood for longer time. This indicates the potential use of transdermal patches in the treatment of Alzheimer disease.

We also recommend Trading Suppliers and Manufacturers of Rivastigmine (cas 123441-03-2). Pls Click Website Link as below: cas 123441-03-2 suppliers

Prev:Paroxetine and Rivastigmine (cas 123441-03-2) mitigates adjuvant-induced rheumatoid arthritis in rats: Impact on oxidative stress, apoptosis and RANKL/OPG signals
Next:Synthesis of 1-amino-2,2-dialkylcyclopropanecarboxylic acids from β-chloroaldimines)